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Summary
The MOZ-TIF2 fusion is associated with acute myeloid leukemia (AML) with inv(8)(p11q13). MOZ is a MYST family histone
acetyltransferase (HAT), whereas TIF2 is a nuclear receptor coactivator that associates with CREB binding protein (CBP).
Here we demonstrate that MOZ-TIF2 has transforming properties in vitro and causes AML in a murine bone marrow
transplant assay. The C2HC nucleosome recognition motif of MOZ is essential for transformation, whereas MOZ HAT
activity is dispensable. However, MOZ-TIF2 interaction with CBP through the TIF2 CBP interaction domain (CID) is essential
for transformation. These results indicate that nucleosomal targeting by MOZ and recruitment of CBP by TIF2 are critical
requirements for MOZ-TIF2 transformation and indicate that MOZ gain of function contributes to leukemogenesis.
Introduction 1996). MOZ contains a C4HC3 type PHD zinc finger domain,
which may serve as a protein-protein interaction domain (Bor-
Acute myeloid leukemias (AML) are disorders of hematopoietic row et al., 1996), an atypical C2HC zinc finger domain with
progenitors characterized by acquired somatic mutations that putative nucleosome binding activity, and a region with homol-
frequently target transcription factors and transcriptional coacti- ogy to the active acetyl-coA binding site of several HAT proteins
vators. Fusion genes involving transcriptional coactivators that from yeast to Drosophila (Chakraborty et al., 2001). The precise
are expressed as a consequence of chromosomal transloca- function of MOZ is not known, but MOZ displays HAT activity
tions in AML include MLL/CBP (Satake et al., 1997; Sobulo et (Champagne et al., 2001; Kitabayashi et al., 2001a), suggesting
al., 1997; Taki et al., 1997), MLL/p300 (Ida et al., 1997), MOZ/ that it might be involved in the regulation of transcription and
CBP (Borrow et al., 1996), MOZ/p300 (Chaffanet et al., 2000; chromatin function. Moreover, MOZ possesses a transcriptional
Kitabayashi et al., 2001b), MORF/CBP (Panagopoulos et al., repression domain at the N terminus and an activation domain
2001), and MOZ-TIF2 (Carapeti et al., 1998; Liang et al., 1998). at the C terminus and may thus be involved in both negative and
Each of these fusion proteins contains one or more histone positive regulation of transcription. For example, MOZ regulates
acetyltransferase (HAT) domain(s) that modify chromatin by transcriptional activation mediated by the hematopoietic tran-
scription factor, Runx1 (AML1) (Kitabayashi et al., 2001a) andacetylation of the N-terminal histone tail.
MOZ (monocytic leukemia zinc finger) belongs to the MYST a related osteogenic transcriptional factor, Runx2 (Pelletier et
al., 2002).family of histone acetyltransferases and was first cloned as a
fusion partner of CBP as a consequence of t(8;16)(p11;p13) TIF2 is a member of the p160 nuclear receptor transcrip-
tional coactivator family (NRCoAs) (Horwitz et al., 1996; Glassassociated with the FAB M4/M5 subtype of AML (Borrow et al.,
S I G N I F I C A N C E
The MOZ-TIF2 fusion is one of several fusion proteins associated with AML that involve transcriptional coactivators, including the
MOZ/CBP, MLL/CBP, and MLL/p300 fusions. We demonstrate that transformation by MOZ-TIF2 in vitro and in vivo requires recruitment
of CBP through the TIF2 and LXXLL motifs, and thus each of these fusion proteins aberrantly recruits the coactivators CBP or p300.
However, in contrast with previous reports that CBP deficiency contributes to pathogenesis of malignancy in humans and in murine
models, our data are most consistent with the hypothesis that CBP contributes an oncogenic, rather than tumor-suppressive, function
to myeloid transformation by MOZ-TIF2.
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et al., 1997) that stimulates gene expression by facilitating the
assembly of basal transcription factors into a stable preinitiation
complex (Klein-Hitpass et al., 1990). The p160 family, including
SRC-1, TIF2/GRIP1, and ACTR/RAC3/pCIP/AIB-1, interacts with
nuclear receptors in a ligand-dependent manner and enhances
transcriptional activation by the receptor via histone acetylation/
methylation (Leo and Chen, 2000).
The p160 family of coactivators have a common domain struc-
ture, with a conserved N-terminal bHLH-PAS domain, a centrally
located receptor interaction domain (RID), and a C-terminal tran-
scriptional activation domain (AD). The RID contains three con-
served motifs, LXXLL (where L is leucine and X is any amino
acid), that are required to mediate interactions between coacti-
vators and liganded nuclear receptors (Heery et al., 1997; Tor-
chia et al., 1997; Ding et al., 1998). TIF2, as well as SRC-1 or
pCIP, interacts directly with CBP via three conserved imperfect
LXXLL motifs in the CBP interaction domain (Torchia et al.,
1997; Demarest et al., 2002).
The MOZ-TIF2 fusion protein retains the C4HC3 type PHD
zinc finger domain, and the HAT (MYST) domain of MOZ. The
TIF2 moiety in MOZ-TIF2 retains the CBP interaction domain
(CID) and CBP-independent activation domain (called AD2) of
TIF2 (Figure 1A). MOZ-TIF2 lacks the C terminus of MOZ and
the PAS/bHLH DNA binding/protein heterodimerization domain
and nuclear receptor interaction domain of TIF2.
We demonstrate here the transforming properties of MOZ-
TIF2 in primary murine hematopoietic progenitors in vitro and
in vivo. Mutational analysis was performed to determine the role
of the various functional domains retained in the MOZ-TIF2
fusion. Our data are consistent with the hypothesis that MOZ-
TIF2 results in MOZ gain of function through recruitment of
CBP to the nucleosome by the MOZ C2HC domain and suggest
the novel finding that CBP contributes an oncogenic, rather
than tumor-suppressive, function to myeloid transformation by
Figure 1. Schematic diagram and Western blot analysis of MOZ, TIF2, MOZ-
MOZ-TIF2. TIF2 fusion, and MOZ-TIF2 deletion mutants
A: Two variants of MOZ-TIF2 have been reported in the literature. Arrow
Results indicates the breakpoint region in the inv(8). Domains for MOZ are as follows:
PHD, plant homeodomain zinc fingers; HAT, histone acetyltransferase or
MYST, [MOZ, YBF2/SAS3, SAS2, TIP60]. Domains for TIF2 are: CID, CBP interac-MOZ-TIF2 immortalizes primitive myeloid progenitors,
tion domain; and RID, nuclear receptor interaction domain; PAS/bHLH, DNAand immortalization is dependent on the MOZ MYST
binding/protein heterodimerization domain; AD2, activation domain 2.
domain and the TIF2 CID B: The fusion retains the PHD domain and the HAT domain of MOZ and the
The transforming properties of MOZ-TIF2 and related mutants CID and the AD2 domains of TIF2.
C: Western blot analysis of MOZ-TIF2 and related deletion mutants expressedwere studied in vitro by retroviral transduction of murine bone
from the MSCV constructs in transiently transfected 293T cells using anti-M2marrow cells in a serial replating assay (Lavau et al., 1997,
Flag antibody.2000a, 2000b; Slany et al., 1998; DiMartino et al., 2000). MOZ-
TIF2 mutants included deletions of the PHD domain of (del
PHD/TIF2), the MOZ HAT domain (del HAT/TIF2), the TIF2/CBP
interaction domain (MOZ/del CID) and a fusion in which only empty vector controls (Figure 2A, first round). This is probably
the TIF2 CBP interaction domain was present (MOZ/CID) (Figure due to lower viral titers of MOZ-TIF2 constructs compared with
1B). We confirmed the protein expression of MOZ-TIF2 or mu- empty vector, as a consequence of inefficient viral packaging
tants in 293T cells transiently transfected with flag-tagged of the large MOZ-TIF2 constructs.
MSCV constructs by Western blotting (Figure 1C). First round colonies were harvested, and 104 cells were
Bone marrow cells transduced with MOZ-TIF2 or deletion plated in secondary methylcellulose cultures. In second round
mutants were plated in methylcellulose cultures supplemented cultures, MOZ-TIF2-transduced cells produced hundreds of
with SCF, IL-3, and IL-6. G418 was also added to first round large, compact colonies with primitive GM morphology. Among
cultures to select for transduced cells. In the first round of the various deletion mutants, del PHD/TIF2 and MOZ/CID gen-
plating, numerous colonies were observed for cells transduced erated secondary colonies, whereas cells transduced with del
with MOZ-TIF2 or related deletion mutants as well as empty HAT/TIF2, MOZ/del CID, or empty vector control produced no
vector, reflecting the normal clonogenic potential of progenitors colonies (Figure 2A, second round). This effect was sustained
harvested from 5-FU-treated bone marrow. Fewer first round through a subsequent third round of plating (Figure 2A, third
round). These data indicate that the MOZ HAT and TIF2 CIDcolonies were observed with MOZ-TIF2 or deletion mutants than
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domains are required for in vitro transformation, whereas the
MOZ PHD domain and the putative acetyltransferase domain
(AD2) of TIF2 are not required for transformation.
We also tested the myeloid immortalization capacity of
MOZ-TIF2 with a growth factor cocktail including macrophage
colony-stimulating factor (GM-CSF). MOZ-TIF2 was unable to
immortalize myeloid progenitors under these conditions (data
not shown).
To determine whether MOZ-TIF2-transduced cells were ca-
pable of sustained growth in suspension cultures, colonies from
MOZ-TIF2 third round platings were replated for one additional
round with various combinations of cytokines. Each culture was
initiated with 104 cells. As shown in Figure 1B, MOZ-TIF2-trans-
duced cells produced almost the same number of myeloid colo-
nies with IL-3 alone or the growth factor cocktail including IL-3.
In contrast, no colonies were observed without IL-3 (Figure 2B).
These data indicate that cells immortalized by MOZ-TIF2 require
exogenous IL-3 for sustained viability or growth.
MOZ-TIF2 induces acute myeloid leukemia in a murine
bone marrow transplant assay
To assess in vivo transforming properties of MOZ-TIF2, we
performed murine bone marrow transplant assays as described
(Schwaller et al., 1998; Liu et al., 2000). Briefly, whole bone
marrow harvested from 5-fluorouracil-primed mice was trans-
duced with retrovirus containing the MOZ-TIF2 fusion gene. The
retroviral vector contained a cassette with an internal ribosomal
entry site (IRES) and EGFP. MOZ-TIF2-transduced bone marrow
cells were introduced by tail vein injection into lethally irradiated
syngeneic recipient mice. In control experiments, mice trans-
planted with bone marrow cells transduced with retrovirus con-
taining either MOZ or TIF2 wild-type genes did not develop
hematological disease with a followup of more than 280 days
(data not shown).
In contrast, animals transduced with cells containing either
the MOZ-TIF2(I) or MOZ-TIF2(II) variant fusion genes developed
fatal hematopoietic malignant disease with a median latency
of 93 days or 90 days, respectively. The disease was readily
transplantable into secondary recipients with a shorter disease
latency of 35–42 days (Figure 2C and Table 1). Gross pathologi-
cal analysis revealed generalized lymphadenopathy, including
axillary, mesenteric, paraaortic, and femoral nodes in all dis-
eased mice. In addition, all mice had widespread infiltration of
tumor within the cervical nodes and salivary glands, spreading
in some cases and involving the entire cranio/facial region. Addi-
tional features of malignancy included splenomegaly (150 mg–
500 mg) and hepatomegaly (Table 1). We consistently observed
elevated white blood cell (WBC) counts that ranged from 30 Figure 2. Transforming activity of MOZ-TIF2 and related mutants in serial re-
106/ml to as high as 220  106/ml (Table 1). These cells wereplating and BMT assays
predominantly comprised of mature myeloid and monocyticA: Number of first, secondary, and tertiary colonies (from left to right) gener-
ated per 104 input cells seeded following methylcellulose culture of bone forms, including admixed immature myeloid elements, many
marrow cells transduced with the MOZ-TIF2 or deletion mutants. The values with monocytic features, and occasional leukemic blast forms
shown are the mean of two independent experiments with duplicate. (Figure 3A-a). The majority of cells observed in lymph node
B: Number of colonies generated from MOZ-TIF2 third round platings with
various combinations of cytokines.
C: Kaplan-Meier comparative survival analysis of MOZ-TIF2 and deletion
mutants. BMT cumulative survival was plotted against days posttransplanta-
tion. Mice transplanted with primary murine bone marrow transduced with
MOZ-TIF2(I) (n  14), MOZ-TIF2(II) (n  9), del PHD/TIF2 (n  7), or MOZ/CID rally transduced with del HAT/TIF2 or MOZ/del CID developed no disease
(n  9) developed AML with a median latency of 91, 92, 117 or 73 days, with an observation period of more than 300 days. Eight control mice trans-
respectively. A secondary BMT (n  4) using 1  106 cells from the cervical planted with bone marrow transduced by retrovirus containing either the
node of MOZ-TIF2(I) diseased mice caused AML rapidly with a median wild-type MOZ or TIF2 were alive and well up to 280 days posttransplantation
latency of 40 days. In contrast, mice transplanted with bone marrow retrovi- (not shown).
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Figure 3. Histopathologic, flow cytometric, and clonality analysis of mice transplanted with MOZ-TIF2-transduced bone marrow
A: (a) Peripheral blood smears (Wright-Giemsa stain) showed a moderate leukocytosis consisting predominantly of mature and immature myeloid cells,
many with monocytic features and occasional blast forms. (b) A touch preparation of cervical lymph node (Wright-Giemsa stain) showed large immature
myeloid forms with high nuclear to cytoplasmic ratios. (c) Representative bone marrow from an affected mouse showed that the majority of the cellularity
was comprised of sheets of immature myeloid cells with oval to irregular nuclei, 1–3 distinct nucleoli, and small to moderate amounts of eosinophilic
cytoplasm. Also present were smaller numbers of mature myeloid cells. The features were consistent with involvement by a myeloid leukemia. (d) Spleens
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Table 1. Summary of bone marrow transplant experiments with MOZ-TIF2 and deletion mutants
No. of diseased Disease latency WBC  106 per ml Spleen weight,
Construct mice/BMT mice (median) (median) mg (median)
MOZ-TIF2(I) 14/14 36–207 (91) 30–220 (71) 170–540 (388)
MOZ-TIF2(II) 9/9 77–270 (92) 17.5–159 (57) 260–390 (300)
del PHD/TIF2 7/7 78–138 (117) 27–215 (92) 210–590 (510)
MOZ/CID 9/9 47–84 (73) 59–254 (115) 120–570 (310)
2nd BMT (MOZ/TIF2(I)) 4/4 35–42 (42) 70–92 (80) 250–715 (525)
del HAT/TIF2 0/8 No disease 300 days
MOZ/del CID 0/8 No disease 300 days
Note: Normal WBC count is up to 15  106 per ml and normal spleen weight is up to 150 mg.
touch preparations were immature myeloid cells including large EGFP on single cell suspensions from the spleen of diseased
animals transplanted with MOZ-TIF2 demonstrated that 30%–immature myeloid forms with high nuclear to cytoplasmic ratios
(Figure 3A-b). 60% of cells in the spleen were positive for EGFP (Figure 3B,
Ungated). When gated for EGFP, the vast majority of cells wereHistological examination of tissues from diseased animals
demonstrated systemic involvement by a similar population of positive for Mac-1, confirming the myeloid lineage of these cells.
A fraction of Mac-1-positive cells (40%) also expressed themyeloid leukemia cells. Bone marrow (Figure 3A-c) revealed
sheets of immature myeloid cells with oval to irregular nuclei, 1–3 mature granulocytic marker Gr-1 (Figure 3B, EGFP-Gated) al-
though at lower levels than observed on mature granulocytes.distinct nucleoli, and small to moderate amounts of eosinophilic
cytoplasm. Also present were smaller numbers of maturing my- The mature monocyte- or macrophage-specific marker, F4/80,
was not detected on these cells (data not shown). None of theeloid cells. All spleens from representative diseased mice had
marked expansion of the red pulp by extramedullary hematopoi- EGFP-gated populations infiltrating affected tissues expressed
B (CD19) or T (Thy-1.2) lymphocyte markers (Figure 3B, EGFP-esis composed predominantly of sheets of myeloid elements
demonstrating a limited degree of maturation and fewer num- Gated). There was no CD34 expression on these cells and low
levels of expression of c-kit, a marker associated with primitivebers of erythroid islands and megakaryocytes (Figure 3A-d).
Mesenteric lymph nodes from representative mice showed hematopoietic cells (Figure 3B, EGFP-Gated). These results in-
dicate that the cells infiltrating the affected tissues are relativelymarked lymphoid depletion and diffuse effacement of the nodal
architecture by a homogeneous population of immature myeloid immature myeloid cells with partial granulocytic differentiation.
cells with varying degrees of differentiation (Figure 3A-e). In
addition, the liver revealed a predominantly periportal, perivas- The MOZ MYST domain and the TIF2 CBP interaction
domain are essential for leukemogenesiscular, and sinusoidal mononuclear infiltrate, comprised predom-
inantly of immature myeloid forms similar to the bone marrow Deletion mutants of MOZ-TIF2 were next tested in the murine
BMT model. Functional domains required for MOZ-TIF2 leuke-and splenic infiltrates (Figure 3A-f). Of note, salivary glands
(Figure 3A-g) in most of the animals had infiltrates morphologi- mogenesis correlated with the results from the serial replating
assay. The del PHD/TIF2 or MOZ/CID mutants caused fatalcally identical to those seen in the liver, spleen, lymph nodes,
and marrow, with extensive salivary gland destruction in the hematologic malignancy in all animals with a median latency of
113 days or 73 days, respectively (Figure 2C and Table 1). Inmajority of cases. The lungs showed an interstitial infiltrate of
immature and maturing myeloid forms (Figure 3A-h), and the contrast, deletion mutants lacking the MOZ MYST domain or
the TIF2 CID did not cause hematological disease within ankidneys in the majority of animals had scattered perivascular
myeloid infiltrates (Figure 3A-i). observation period of 330 days (Figure 2C and Table 1). Histo-
pathological and flow cytometric analyses showed that the dis-Flow cytometric analysis for lineage-specific antigens and
from representative MOZ-TIF2 animals showed expansion of red pulp by sheets of immature and maturing myeloid forms. (e) A mesenteric lymph node
mass from a representative mouse showed marked lymphoid depletion and diffuse effacement of the nodal architecture by a homogeneous population
of immature myeloid cells with varying degrees of differentiation. (f) Livers from representative diseased animals showed extensive perivenular and sinusoidal
mononuclear infiltrates, comprised predominantly of immature myeloid forms similar to the bone marrow and splenic infiltrates. (g) Salivary glands in some
diseased animals demonstrated infiltrates morphologically identical to those seen in the liver, spleen, lymph nodes, and marrow. Extensive salivary gland
destruction was present in the majority of cases. (h) Lungs demonstrated an interstitial infiltrate of immature and maturing myeloid forms. (i) Kidneys in the
majority of animals demonstrated scattered perivascular myeloid infiltrates.
B: Flow cytometric analysis of spleens following transplantation of mice with bone marrow transduced with MOZ-TIF2 or delHAT/TIF2. Spleen cells were
stained with a combination of antibodies to Mac-1 and Gr-1, Thy1.2 and CD19, or c-kit and CD34. Dot plots of cell gated on scatter profile only (Ungated)
or scatter profile and EGFP expression (EGFP Gated) are shown in left panels and right panels, respectively. Splenic cells show a predominant population
of EGFP-positive cells that expresses myeloid markers (Mac-1 and/or Gr-1) and lacks staining for B cell (CD19) and T cell (Thy-1.2) markers. A few of these
cells also express c-kit. A major subset of these cells in the spleen demonstrates strong Mac-1 staining with low to absent amounts of Gr-1, indicating that
the leukemic cells were relatively immature myeloid cells with partial granulocytic differentiation.
C and D: Proviral integration and clonality of mice with bone marrow transduced with MOZ-TIF2. Southern blot analysis of DNA isolated from various tissues
of primary recipients with various MSCV-EGFP constructs. Sp, spleen; BM, bone marrow; PB, peripheral blood; LN, lymph node. NheI cuts in the viral LTR
producing a band of expected size in tissues that contain provirus. EcoRI cuts once in the provirus, resulting in bands of different sizes corresponding to
different genomic integration sites. One discrete band can be seen indicating the clonal nature of disease in these tissues.
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Figure 4. Structure and enzymic activity of MOZ-TIF2 point mutants
A: Schematic diagram of mutations. Conserved amino acids C of C2HC zing finger or G of Ac-CoA binding motif in HAT domain were replaced with G
(MOZ-TIF2 C543G) or E (MOZ-TIF2 G657E), respectively. The MOZ-TIF2 LXXLL mutant was generated by replacing amino acid residues in the first two LXXLL
motifs (PDDLL→PAAAA and LLDQL→AADGA) in the CID.
B: Transient transfection followed by Western blot analysis of FLAG-tagged mutants demonstrated expression of the appropriate size protein for each
mutant.
C: MOZ HAT activity is abrogated in the C543G or G657E mutants. Bacterially expressed fusion proteins of the E. coli maltose binding protein (MBP) and
segments of human MOZ were affinity purified and tested for histone acetyltransferase (HAT) activity using filter binding assays. Incorporation of tritiated
acetyl coenzyme A into free calf thymus histones was catalyzed by affinity-purified MBP-MOZ wild-type or mutant fusion proteins. The MYST domain of MOZ
demonstrated histone acetyltransferase activity (pMAL-MOZ-WT). Fusions encoding a point mutation within the C2HC zinc finger (C543G) or a point mutation
within the acetyl coenzyme A binding motif (G657E) demonstrated abrogation of HAT activity. The maltose binding protein tag present in the empty vector
(c2x) did not demonstrate HAT activity.
D: Gel analysis of 2 g of affinity-purified MBP and MBP-MOZ proteins used in HAT assays.
ease caused by the del PHD/TIF2 or MOZ/CID constructs was identified intact proviral integration as a single band of the ex-
pected size in spleen, bone marrow, peripheral blood, and mes-AML, indistinguishable from disease induced by full-length
MOZ-TIF2 (Table 1). enteric lymph node from animals transplanted with bone marrow
cells transduced with MOZ-TIF2, del PHD/TIF2, or MOZ/CID,To verify the presence of the MOZ-TIF2 and related mutant
proviruses in the affected tissues, Southern blot analyses were reflecting the pattern of widespread disease seen on histopatho-
logical examination (Figure 3C).performed on genomic DNA isolated from various tissues using
an EGFP probe. Genomic DNA was digested with NheI, which Clonality of tumors was assessed using EcoRI, which
cleaves once in the integrated provirus. We typically observedcleaves in each of the flanking LTRs within the retrovirus. We
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distinct 1-2 integration sites in various tissues analyzed (Figure
3D), indicating that the tumors were monoclonal or biclonal in
nature. These data suggest that secondary mutations may be
required for the development of the AML phenotype.
The MOZ C2HC nucleosome binding motif is essential
for transformation, whereas acetyltransferase
activity is dispensable
In vitro and in vivo structure-function analysis showed that the
MOZ HAT domain was essential for MOZ-TIF2-mediated trans-
formation. Like other MYST family members, the MOZ HAT
domain contains both a C2HC zinc finger nucleosome binding
motif and an acetyl transferase catalytic domain that binds to
acetyl-Co-enzyme A (Ac-CoA) (Figure 4A) (Sterner and Berger,
2000). Mutational analyses of the yeast and Drosophila homo-
logs of MOZ (Sas3 and Mof, respectively) have shown that both
the C2HC zinc finger domain and Ac-CoA binding domain are
required for HAT activity (Takechi and Nakayama, 1999; Akhtar
and Becker, 2000). Moreover, the Mof C2HC zinc finger motif
is required for binding to the nucleosome (Akhtar and Becker,
2001).
To determine the relative contributions of these functional
motifs within the MOZ MYST domain, we generated point muta-
tions in MOZ-TIF2 at amino acid residues C543G and G657E,
respectively (Figure 4A). These are homologous to mutations
that abrogate C2HC nucleosome binding or acetyltransferase
activity, respectively, in the context of the MOZ homologs Sas3
and Mof (Takechi and Nakayama, 1999; Akhtar and Becker,
2000, 2001).
We confirmed predicted functional effects of these muta-
tions by expressing the MYST domain of MOZ with the point
mutation in the C2HC zinc finger domain (C543G) or the Ac-
CoA binding site (G657E) in E. coli. HAT activity was determined
by measuring the incorporation of [3H]acetyl CoA into calf thy- Figure 5. Myeloid immortalization assays and Kaplan-Meier comparative
mus histones in liquid assays. HAT activity of MOZ was com- survival analysis of MOZ-TIF2 point mutants
pletely abrogated by either the C543G mutant or the G657E A: Numbers of primary, secondary, and tertiary colonies (from left to right)
mutant, a finding that is consistent with a requirement for the generated per 104 input cells transduced with MOZ-TIF2 and related mu-
tants. The values shown are the mean to two independent experimentsconserved MOZ C2HC zinc finger motif and the Ac-CoA binding
with duplicate values.motif for binding to and acetylation of histones, respectively
B: Kaplan-Meier plot of survival. Over 150 days, mice transplanted with
(Figures 4C and 4D). primary bone marrow cells transduced with MOZ-TIF2 (n  8) or MOZ-TIF2
The mutants were next tested in the serial replating and G657E (n  8) developed hematologic disease with an 88% penetrance
(all AML) or 50% penetrance (three AML and one T cell lymphoma), respec-murine BMT assays. In both assays, the C543G mutation re-
tively. In constrast, mice transplanted with bone marrow retrovirally trans-sulted in complete loss of transformation, indicating that nu-
duced with MOZ-TIF2 C543G (n  9) or LXXLL (n  8) mutations developedcleosome binding motif was essential. In contrast, the G657E
no disease.
Ac-CoA binding mutant retained transforming ability in both
assays, indicating that MOZ acetyltransferase activity was dis-
pensable (Figures 5A and 5B). Although penetrance of AML was
reduced to 50%, the latency was identical to MOZ-TIF2. One leukemogenesis by MOZ-TIF2 because the MOZ-TIF2 mutant
animal transplanted with the G657E mutant developed a T cell lacking the TIF2 CID abrogated transformation in vitro and in
malignancy (data not shown), but the others developed AML vivo. In contrast, a mutant in which MOZ was fused to only the
that was indistinguishable from the MOZ-TIF2 phenotype by TIF2 CID domain, and lacking the TIF2 AD2 carboxy-terminal
histopathology or flow cytometry. Thus, the Ac-CoA binding domain, retained full transforming properties.
motif is dispensable for development of AML, but its absence To verify this hypothesis, we tested for CID-mediated asso-
may affect the penetrance and, in some instances, phenotype ciation of MOZ-TIF2 with CBP using GST pulldown assays. A
of disease. GST-CBP (murine CBP amino acids 2040–2200, containing the
p160 interaction domain of CBP) fusion protein expressed in E.
Recruitment of CBP by MOZ-TIF2 is required coli was used for experiments with in vitro translated MOZ-TIF2
for transformation and related mutants. MOZ-TIF2, del PHD/TIF2, del HAT/TIF2,
TIF2 activity is stimulated through interaction with CBP via the and MOZ/CID all associated with GST-CBP (Figure 6). In con-
CBP interaction domain (CID) (Voegel et al., 1998). We hypothe- trast, only MOZ/del CID did not bind to GST-CBP, indicating
that MOZ-TIF2 associates with CBP through the TIF2 CID.sized that the recruitment of CBP by TIF2 CID contributed to
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disease (Figure 5B). These data indicate that the conserved
LXXLL motifs in the TIF2 CID that are required for CBP interac-
tion are necessary for in vitro and in vivo transformation medi-
ated by MOZ-TIF2. Collectively, these findings demonstrate that
the association between MOZ-TIF2 and CBP through the TIF2
CID plays a pivotal role in MOZ-TIF2-mediated transformation
(Figure 7).
Discussion
In this study, we demonstrate that MOZ-TIF2 immortalizes my-
eloid progenitors in vitro and induces AML in mice. The murine
disease shares many features with human leukemias that ex-
press MOZ-TIF2 as a consequence of inv(8)(p11q13). Our suc-
cessful modeling of this leukemia in mice reveals several impor-
tant aspects of its pathogenesis and demonstrates the in vivo
myeloid transforming properties of MOZ-related fusion proteins,
which also include MOZ/CBP and MOZ/p300.
Our studies suggest that MOZ-TIF2 specifically cooperates
with the IL-3 signaling pathway to facilitate immortalization since
IL-3 was found to be necessary and sufficient for maintenance
of in vitro clonogenic activity of myeloid progenitors transduced
with MOZ-TIF2. Conversely, GM-CSF appeared to antagonize im-
mortalization, suggesting that signaling via the GM-CSF receptor
pathway in primary target cells induces terminal differentiation
independent of MOZ-TIF2 expression and/or the presence of
other cytokines such as IL-3. However, after establishment of
MOZ-TIF2-immmortalized myeloid progenitors in vitro, GM-CSF
was unable to overcome IL-3-mediated clonogenic activity, sug-
gesting that MOZ-TIF2-immortalized cells become nonresponsive
to GM-CSF. Thus, MOZ-TIF2-immortalized cells are phenotypi-
cally distinct from the initial target populations from which they
are derived. Attenuation of GM-CSF-mediated terminal differen-
tiation may be due to receptor downregulation or functional loss
of essential downstream signaling components. This contrasts
with the effects of various MLL fusion proteins, which immortal-
ize myeloid progenitors in vitro in the presence of multiple cyto-
kines including GM-CSF (reviewed in Ayton and Cleary, 2001)
and are thought to act via abrogation of both IL-3- and GM-
CSF-mediated terminal differentiation.
Animals transplanted with MOZ-TIF2-transduced cells de-
veloped AML with 100% penetrance with a relatively short la-Figure 6. MOZ-TIF2 interacts with CBP
tency. The phenotype of these animals was similar in manyIn vitro translated and 35S-labeled MOZ-TIF2 or related deletion mutants
were incubated with beads absorbed with GST (lane 2) or GST-CBP (murine ways to the AML phenotype associated with inv(8) in humans,
CBP aa2040–2200) (lane 3). Labeled peptides retained on the beads were including a predominance of myeloid cells with features of im-
released and analyzed by SDS-PAGE and autoradiography, together with mature monocytes. AML was readily transplantable to second-
15% of the translated products used in the incubation (INPUT, lane 1).
ary recipients, suggesting that the disease may arise from stem
cells or immature progenitors with self-renewal capacity. The
mono- or oligo-clonality of the disease as well as the defined
latency indicate that secondary mutations are required for pro-We tested the transforming properties of MOZ-TIF2 with
gression to a fully malignant AML phenotype. The nature ofloss-of-function point mutations in the LXXLL motif that is re-
potential secondary mutations is suggested by the recent reportquired for CBP interaction (Voegel et al., 1998). The first two
that an AML with inv(8) also contained an internal tandem dupli-LXXLL motifs (PDDLL→PAAAA and LLDQL→AADGA) in the CID
cation (ITD) of the FLT-3 receptor (Billio et al., 2002). FLT-3 ITDwere mutated (Figure 4A). In the serial replating assay, this
results in constitutively activated tyrosine kinase activity that ismutant (MOZ-TIF2 LXXLL) did not generate any colonies in
sufficient to induce myeloproliferative disease (but not AML) insecond and third round replatings, indicating that the LXXLL
a murine bone marrow transplant model (Kelly et al., 2002). Thus,mutations in the TIF2 CID abolished the immortalization proper-
constitutive activation of the FLT-3 pathway may represent aties of MOZ-TIF2 in this assay (Figure 5A).We next tested the
candidate secondary mutation that cooperates with MOZ-TIF2transforming properties of the MOZ-TIF2 LXXLL mutants in vivo.
to abrogate factor dependence and induce AML.None of eight animals transplanted with bone marrow retrovirally
transduced with MOZ-TIF2 LXXLL developed hematological Mutational analysis of MOZ-TIF2 suggests a mechanistic
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Figure 7. Model for transformation mediated by
the MOZ-TIF2 fusion protein
Wild-type MOZ binds to nucleosomes via the
C2HC domain and mediates acetylation of his-
tones through HAT activity in the MYST domain.
The MOZ-TIF2 fusion recruits CBP to the nucleo-
some and results in aberrant acetylation of his-
tones, and perhaps of critical associated tran-
scription factors, resulting in leukemia with
complete penetrance. Mutation C543G abro-
gates nucleosome binding activity of MOZ-TIF2
and results in abrogation of leukemia in that nei-
ther the MOZ MYST domain nor the CBP HAT ac-
tivity recruited through the TIF2 CBP interaction
domain are targeted to nucleosomes. The MOZ
G657E mutation that abrogates MOZ HAT activity
attenuates but does not eradicate transforming
activity in that CBP HAT activity can still be re-
cruited to the nucleosome via the MOZ-TIF2 fu-
sion. Finally, mutation of the TIF2 LXXLL motif re-
quired for CBP interaction results in abrogation
of leukemia due to a lack of CBP recruitment.
Collectively, these data suggest that MOZ-TIF2-
induced leukemias require recruitment of CBP
to MOZ nucleosome binding sites, and are the
consequence of a MOZ gain-of-function muta-
tion. Further, the model suggests that CBP can
act as an oncogene. Abbreviations: Ac  acet-
ylation site; C MOZ C2HC nucleosome binding
domain; TF  transcription factor. Green indi-
cates MOZ and related mutants, yellow indicates
CBP. Ac within the MOZ and CBP proteins indi-
cates acetyl-CoA transferase domain.
basis for its oncogenic function. The PHD zinc finger domain these two subdomains of MOZ-TIF2 were evaluated following
their functional inactivation by point mutations. The C543G mu-at the N terminus of MOZ is dispensable for transformation,
indicating that transcriptional repression previously associated tation is precisely analogous to a mutation that abrogates
nucleosome recognition and binding of the Drosophila orthologwith this domain (Champagne et al., 2001) is not required for
transformation by MOZ-TIF2. Moreover, loss of the C terminus of MOZ, Mof. The observation that either the C543G or the
G567E mutation abrogates HAT activity in MOZ is consistentof MOZ as a consequence of chromosomal translocation is not
sufficient for leukemogenesis since a mutant lacking the TIF2 with a conserved function for these residues in MOZ and Mof,
but would be further strengthened by direct demonstration thatmoiety is not transforming. In contrast, deletion of the MOZ
HAT domain abrogated MOZ-TIF2-mediated transformation. C543G results in loss of nucleosome binding in vitro. Taken
together, however, these data are consistent with the hypothesisThe HAT (or MYST) domains of MYST family proteins contain
two tandem motifs that are highly conserved from yeast to that target recognition, rather than MOZ-mediated acetylation,
is a critical contribution of MOZ to the transformation propertiesmammals. The first conserved motif is an atypical C2HC zinc
finger motif, which in the MOZ-related protein Mof, has been of MOZ-TIF2.
With respect to TIF2, our studies indicate that the CID isdemonstrated to be a nucleosome recognition domain (Akhtar
and Becker, 2001). The second motif encodes an acetylcoen- necessary and sufficient to activate the oncogenic potential of
MOZ since a MOZ/CID mutant that retains only the CID fromzyme A (acetyl CoA) binding domain (also seen in other HATs),
which transfers the acetyl moiety from acetyl CoA onto one or TIF2 shows full transforming properties in vitro and in vivo. This
mutant fusion protein lacks numerous TIF2 domains requiredmore lysine residues contained within the N-terminal tails of
histones (Grant and Berger, 1999). The relative contributions of for DNA binding and protein heterodimerization (bHLH PAS
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domain), nuclear receptor interaction (RID), and potential HAT function, then it could be predicted that the MOZ nucleosomal
activity (AD2) (Figure 1), indicating that these domains of TIF2 recognition motif would not be required for transformation. How-
are also dispensable for transformation. We further demonstrate ever, MOZ-TIF2 with a point mutation in the C2HC nucleosome
that MOZ-TIF2 associates with CBP through the TIF2 CID and recognition motif is not transforming. Our data are thus more
that a MOZ-TIF2 LXXLL mutant abrogates transformation. consistent with the hypothesis that MOZ-TIF2 results in MOZ
Our results have three potential implications for the mecha- gain of function through recruitment of CBP to MOZ targets
nistic role of MOZ-TIF2 in mediating leukemic transformation. and suggest the novel finding that CBP contributes an onco-
Firstly, MOZ-TIF2 promotes leukemogenesis through a domi- genic rather than tumor-suppressive function to myeloid trans-
nant gain of MOZ function via direct transcriptional deregulation. formation by MOZ-TIF2. These studies provide insights into the
In such a model, the C2HC zinc finger motif facilitates specific molecular mechanism of transformation mediated by MOZ-TIF2
recognition of nucleosomal components positioned at transcrip- and provide tools for understanding the mechanism of leuke-
tional elements within the regulatory sequences of MOZ target mias mediated by HAT domain fusion proteins.
genes. How the MOZ C2HC motif discriminates nucleosomes
Experimental proceduresand/or DNA sequences in the context of MOZ target genes is
currently unknown. The TIF2 moiety within MOZ-TIF2, no longer
Plasmid and mutant constructionnuclear hormone responsive, may constitutively recruit CBP.
To construct the expression vector pcDNA3-MOZ-TIF2(I), the breakpointOnce recruited to MOZ target genes via the CID within TIF2,
region was PCR amplified from patient cDNA (Carapeti et al., 1998) and
CBP could serve as an aberrant constitutive coactivator. For the ligated to 5 MOZ fragment obtained from pBS-MOZ (kindly provided by J.
related MOZ-CBP fusion protein, the CBP moiety is covalently Borrow) and 3 TIF2 fragment obtained from pSG5-TIF2 (kindly provided by
coupled to MOZ and would therefore also result in constitutive H. Gronemeyer) by two step ligation. pcDNA3-MOZ-TIF2(II), MOZ/delCID,
coactivation of MOZ target genes. Thus, MOZ-TIF2 may mimic and the MOZ-TIF2-LXXLL mutant were kindly provided by K. Blanchard.
pcDNA3-delPHD/TIF2, delHAT/TIF2, MOZ-TIF2-C543G (C2HC finger mu-the MOZ/CBP fusion in the t(8;16) associated with AML M5
tant), and the MOZ-TIF2-G657E (acetyl-CoA binding site mutant) weresubtype (Borrow et al., 1996), and these two fusion proteins may
constructed using site-directed mutagenesis (ExSiteTM PCR-Based; Stra-share overlapping molecular targets that contribute a common
tagene, La Jolla, California) of pcDNA3-MOZ-TIF2(II) according to the manu-pathway to leukemia pathogenesis.
facturer’s instructions. pcDNA-MOZ/CID was constructed by introducing a
CBP transcriptional coactivation requires either CBP HAT MOZ/CID fragment from MSCV2.2 GFP-MOZ/CID (as below) digested with
or the CBP-associated P/CAF HAT activity (Korzus et al., 1998). EcoRI to the EcoRI site of pcDNA.
Thus, CBP-dependent acetylation of nucleosomes may en- The full-length cDNAs were subcloned from pcDNA to MSCV-EB neo
at the EcoRI site or XhoI site, or MSCV2.2 GFP into the EcoRI site or XhoI-hance chromatin accessibility surrounding transcriptional ele-
EcoRI sites. The MSCV-MOZ/CID constructs were generated by digestingments within the regulatory sequences of MOZ target genes,
MSCV-MOZ-TIF2 constructs followed by a self-ligation step that resulted inindirectly facilitating the engagement of additional transcrip-
an out-of-frame fusion 3 of the TIF2 CID.tional complexes that aberrantly initiate and/or maintain MOZ
For analysis of protein expression of pcDNA or MSCV constructs, Kozaktarget gene expression. In support of this model, the MOZ/
and Flag sequences (GCCACC and ATGGATTACAAGGATGACGACGAT
CBP fusion associated with t(8;16) blocks IL-6-induced terminal AAG) were introduced into the 5 portion of the cDNA by site-directed
differentiation of M1 cells in vitro via a HAT domain-dependent mutagenesis and used for Western blotting.
mechanism, suggesting that HAT activity of CBP may have an MOZ cDNA was cloned in-frame into the vector pMAL-c2x (New England
essential role in transformation of certain cell lines (Kitabayashi BioLabs, Beverly, Massachusetts) downstream from the maltose binding
protein (MBP) purification tag to generate the construct pMAL-MOZ. Theet al., 2001a). However, we currently cannot exclude the possi-
constructs pMAL-MOZ-C543G and pMAL-MOZ-G657E were derived frombility that collaboration between MOZ-TIF2 and CBP occurs via
the wild-type construct using site-directed mutagenesis (QuikChange; Stra-a HAT-independent mechanism in which CBP acts as a bridging
tagene).molecule to recruit other transcription factors to MOZ target
pGEX-4T1-CBP, which expressed a glutathione S-transferase (GST)
genes whereby transcriptional activation takes place in a chro- fusion protein containing the p160 family binding domain of murine CBP,
matin environment that is already competent for transcription. was generated by introducing CBP fragment (aa2040-2200) made by PCR
Secondly, histones are not the exclusive in vivo substrates into BamHI-EcoRI sites.
for CBP-associated acetyltransferase activity. CBP also exhibits All constructs were confirmed by DNA sequencing.
factor acetyltransferase (FAT) activity to modulate the function
Myeloid immortalization assayof a growing number of transcription factors including p53 (Gu
Transduction of murine bone marrow (BM) cells was performed essentiallyand Roeder, 1997), hematopoietic cell-specific factor GATA-1
as described previously (DiMartino, et al., 2000). Briefly, 4-week-old C57B/(Boyes et al., 1998), and EKLF (Zhang and Bieker, 1998; Hung
6 mice were injected with 5-FU (150 mg/kg) by tail vein, and bone marrow
et al., 1999). Therefore, aberrant acetylation of these of other
was harvested from both femurs after 5 days. Transient retroviral superna-
as yet undefined transcriptional factors by the MOZ-TIF2-CBP tants were produced by transfecting NX cells with MSCV vectors as de-
complex may contribute to leukemogenesis. scribed previously (Pear et al., 1993). Bone marrow cells were infected with
Thirdly, the interaction of CBP with MOZ-TIF2 may result in recombinant virus by centrifugation at 2500 g for 2 hr at 32C. Transduced
cells were plated in 0.9% methylcellulose (Stem Cell Technologies, Vancou-trans-dominant inhibition of CBP tumor suppressor function.
ver, BC, Canada) supplemented with 20 ng/ml stem cell factor (SCF) andCBP displays tumor suppressor properties in heterozygous
10 ng/ml each of interleukin-3 (IL-3) and IL-6 (R&D Systems, Minneapolis,mice (Kung et al., 2000) as well as humans with Rubinstein-
Minnesota) in the presence or absence of G418 (1 mg/ml). After 7 to 10Taybi syndrome (Petrij et al., 1995), leading to an increased
days, colonies were counted and retroviral transduction efficiency was calcu-
propensity for hematologic malignancies in both settings. How- lated for each construct as the ratio of G418-resistant (G418R) colonies to
ever, we do not favor this possibility in MOZ-TIF2-induced leuke- unselected colonies. Single cell suspensions were made from pooled G418R
mias. If the function of the MOZ-TIF2 fusion were simply to colonies, and 104 cells were plated in secondary methylcellulose cultures
without G418.bind and sequester CBP, resulting in physiologic loss of CBP
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Murine bone marrow transplant assay as dot plots of cells that were gated on the basis of forward and side scatter.
In some experiments, gating for EGFP expression was also done.Retroviral supernatant were generated by transient cotransfection of 293T
cells with the MSCV-IRES-EGFP constructs and packaging plasmid (Ecopac)
using Superfect (Qiagen, Valencia) according to the manufacturer’s instruc- HAT assays
tions. Supernatants were collected 48 hr posttransfection and filtered (0.45 Bacterially expressed MBP and MBP-MOZ proteins were purified on amylose
m). Viral titers were estimated by transduction of Ba/F3 cells in the presence beads according to the manufacturer’s instructions. The concentrations of
of Polybrene (10 mg/ml) as described previously (Liu et al., 2000). Eight days purified MBP proteins were determined spectrophotometrically by compari-
prior to each BMT procedure, 4- to 6-week-old male BALB/c mice (from son to a standard curve prepared using bovine serum albumin. The purity
Taconic, Germantown, New York) were pretreated with 150 mg of 5-fluoro- and integrity of eluted MBP and MBP-MOZ proteins was assessed by SDS-
uracil (5-FU; Sigma) per kg body weight, administered intraperitoneally. Two PAGE. Purified MBP proteins were used in histone acetyltransferase assays.
days prior, bone marrow was harvested from these donor mice by flushing HAT activity was determined by measuring the incorporation of [3H]ace-
femurs and tibias and red blood cells were lysed. Bone marrow cells were tyl CoA (Amersham Biosciences) into calf thymus histones (Type IIA; Sigma
then resuspended in RPMI/10% FBS supplemented with 6 ng/ml recombi- Chemical, St. Louis, Missouri) in liquid assays according to published meth-
nant mouse IL-3 (Genzyme, Cambridge, Massachusetts), 100 ng/ml recom- ods (Mizzen et al., 1999). Ten micrograms of each protein sample was
binant mouse stem cell factor (Genzyme), and 10 ng/ml recombinant mouse assessed for HAT activity in a 50 l reaction buffer containing 5 g calf
IL-6 (PeproTech, Rocky Hill, New Jersey) and cultured overnight at 37C. thymus histones. Incubations were performed for 20 min at 30C. The incor-
Cells were transduced by two rounds of spin infection at 24 hr and 48 hr poration of 3H-acetate into free histone substrates was quantitated by P81
after harvesting. Centrifugation of 1 ml viral supernatant and 4  106 cells filter binding and liquid scintillation. Triplicate 15 l aliquots of each reaction
mix were processed in parallel. The assay was repeated to confirm thein 3 ml transplant media containing 5 g/ml Polybrene and 7.5 mM HEPES
reproducibility of the findings.buffer was carried out for 90 min at 1800 g. Cells were washed in PBS,
resuspended in Hanks balanced salt solution (Life Technologies), and in-
jected (1–2 106 cells/0.5 ml) into the lateral tail vein of lethally irradiated (2 GST pulldown assays with [35S]methionine-labeled proteins
Bacterial lysates containing GST or GST fusion proteins were incubated at450 cGy) female syngeneic recipient mice. Mice were housed in microisolator
4C for 2 hr with Glutathione-Sepharose beads (Pharmacia). 35S-labeledcages with autoclaved chow and acidified water.
samples produced from pcDNA constructs as a template by in vitro transla-
tion using the TNT T7-coupled reticulocyte lysate system (Promega) wereSouthern blot analysis
added to 500 ml of binding buffer (20 mM HEPES [pH 7.8], 75 mM KCl, 0.1Genomic DNA was isolated from tissues using tissue lysis buffer (100 nM
mM EDTA, 2.5 mM MgCl2, 1% skim milk,1 mM DTT, 0.05% NP-40) con-Tris-HCl, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 100 g/ml proteinase K).
taining the preabsorbed beads and then the mixture was incubated at 4CTen micrograms of each DNA was digested with either NheI (cleaves twice,
for 2 hr. Bound proteins were recovered in SDS sample buffer and analyzedat the LTR’s in the provirus) or EcoRI (cleaves once or twice at the upstream
by SDS-PAGE and autoradiography.of EGFP part of retrovirus) and transferred to Hybond N nylon membranes
(Amersham, Arlington Heights, Illinois). Provirus was detected using an EGFP
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